Biogen Q4 revenue $2.3bln, FY25 revenue $9.9bln, exceeding guidance.
ByAinvest
Friday, Feb 6, 2026 7:01 am ET1min read
BIIB--
• Biogen reports Q4 2025 total revenue of $2.3 billion • Q4 GAAP diluted EPS $(0.33) • Q4 non-GAAP diluted EPS $1.99 • Full year 2025 total revenue $9.9 billion • Full year GAAP diluted EPS $8.79 • Full year non-GAAP diluted EPS $15.28 • Growth products up 6% YoY in Q4 • LEQEMBI Q4 global in-market sales $134 million, up 54% YoY • SKYCLARYS Q4 U.S. revenue $89 million • Full year 2026 financial guidance provided
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet